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Abstract 
Schistosoma haematobium antigen recognition profiles of the human isotypes IgA, IgE, IgG1 
and IgG4 were compared by image analysis of western blots. Adult worm antigens 
separated by 2-dimensional gel electrophoresis were probed with pooled sera from 
Zimbabweans resident in a S. haematobium endemic area, followed by identification of 
individual antigenic parasite proteins using mass spectrometry. Overall, IgG1 reacted with 
the largest number of antigens, followed by IgE and IgA which detected the same number, 
while IgG4 detected the fewest antigens. IgE recognised all the antigens reactive with IgG4 
as well as an additional four antigens; an isoform of 28kDaGST, phosphoglycerate kinase, 
actin 1 and calreticulin. IgG1 additionally recognised fatty acid binding protein, triose-
phosphate isomerase, and heat shock protein 70, which were not recognised by IgA. 
Recognition patterns varied between some isoforms e.g. the 2 fructose 1-6-bis-phosphate 
aldolase isoforms differentially recognised by IgA and IgG1. Although the majority of S. 
haematobium adult worm antigens are recognised by all the four isotypes there are clear 
restrictions in antibody recognition for some antigens. This may partly explain differences 
observed in isotype dynamics at a population level. Differential recognition patterns for some 
isoforms indicated in the study have potential importance for vaccine development. 
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Introduction 
Schistosomiasis is a major human parasitic disease in tropical and subtropical 
countries in Africa, the Middle East and South America (1). Urinary schistosomiasis 
caused by Schistosoma haematobium affects over 100 million people and a recent 
survey in sub-Saharan Africa indicated that 70 million individuals had experienced 
haematuria and 32 million dysuria associated with S. haematobium infection (2). 
Furthermore, it was estimated that 18 million people suffered schistosome-related 
bladder wall pathology and 10 million suffered hydronephrosis.  
 
Epidemiological studies in endemic human populations have shown that  
schistosome prevalence and intensity levels rise to peak in childhood (around ages 
9-14) (3) and decline thereafter, so that in any endemic population, children carry the 
heaviest infection levels while adults carry little or no infection. This pattern has been 
taken to reflect the development of immune-meditated resistance to infection/re-
infection (3, 4), and suggests that protective immune responses develop slowly as a 
result of cumulative exposure to parasite antigens (5). Early serum transfer studies in 
the mouse model (6-9) as well as  human immuno-epidemiological studies have 
shown that schistosome-specific antibody responses are associated with protection 
to infection and re-infection (10-14). Despite the demonstration that antibody-
mediated responses can protect against schistosome infection in experimental 
models, current human schistosome vaccine research based on antibody-mediated 
protection has stalled with the failure of many of the vaccine candidate antigens to 
enter Phase III clinical trials (15).  Limitations in our current understanding of the 
development of protective anti-schistosome responses against specific antigenic 
proteins may be contributing to the slow development of effective anti-schistosome 
vaccines. Previous studies characterising immune responses to schistosome 
proteins have relied on recombinant proteins expressed in bacterial systems (16-18). 
However, there are restrictions associated with this approach; for example, it cannot 
detect immunogenic epitopes arising from post-translational modifications. Recent 
developments in 2-dimensional gel electrophoresis and proteomics have the potential 
to overcome some of these restrictions because crude parasite antigen preparations 
can be separated into individual protein spots which can then be identified by mass 
spectrometry analysis and matching to newly-available genomic databases.  
 
The nature of the anti-schistosome antibody response to crude antigen preparations has 
been studied in terms of the different antibody isotypes involved and their relationship to 
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each other, to host age and to schistosome infection level by ourselves and others (for 
example see (5, 12, 19-21, 22 ). Relatively few individual target antigens have been 
analysed in the context of selective antibody isotype recognition (23). IgA, IgE, IgG1 and 
IgG4 are of particular interest as they have been implicated in the development of protective 
human anti-schistosome immunity. Hagan et al demonstrated a significant relationship 
between anti-schistosome IgE and IgG4 responses in S. haematobium infections. 
Furthermore, they reported a decrease in IgG4 accompanied by an increase in IgE with host 
age, which was associated with resistance to re-infection after treatment (11). We have 
previously reported that children exposed to S. haematobium produced a predominantly IgA 
response against egg and adult worm antigens which was gradually replaced by an IgG1 
response in adulthood (5). These studies were based on immune responses to crude 
antigens containing a heterogeneous mixture of proteins and thus did not provide any 
information on the recognition patterns of individual antigens. Therefore the antigenic source 
of variation in isotype-specific responses to S. haematobium is unknown. Differences may 
arise from the recognition of the same antigen by different antibody classes, from the 
recognition of different antigens, or a combination of both. Identifying the individual antigens 
recognised by the different antibody isotypes in crude adult worm antigens would help 
resolve the cause(s) of some of these differences. .In this study, we used proteomic 
approaches in combination with 2-dimensional western blotting to determine which adult 
worm antigens are recognised by specific antibody isotypes/subclasses from schistosome 
infected/exposed individuals. Thus we identify the isotype-specific recognition patterns of 
individual parasite proteins within the crude adult S. haematobium proteome for the first 
time. We identified antigens recognised by IgA, IgE, IgG1 and IgG4, focussing our attention 
on WHO vaccine candidate antigens (24). Characterising the antigens recognised by each 
antibody class will both improve our understanding of naturally acquired schistosome-
specific immunity and inform vaccine development where the aim may be to stimulate an 
isotype-specific antibody response to a single recombinant antigen rather than a 
heterogeneous mixture of peptides.  In this study we determined the reactivity of 
sera from 7-18 year olds the age group where infection levels are changing 
from rising, peaking and declining in this population (25, 26) to capture the 
range or immune reactivities as the dynamics of infection change. The 
analyses were conducted on pre-treatment sera to study natural immune 
reactivities before enhancement of antibody reactivity with anti-helminthic 
treatment which we have previously demonstrated in a different subgroup 
from the same population (27). 
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Materials and Methods 
Study area 
The study was conducted in two rural villages in the Mashonaland East Province of 
Zimbabwe (31o30’E; 17o45’S) where S. haematobium is endemic. The study area is 
described in detail elsewhere (27).  The study received ethical and institutional 
approval from the Medical Research Council of Zimbabwe and the University of 
Zimbabwe respectively. Permission to conduct the work in this province was obtained 
from the Provincial Medical Director. The villages were selected because health 
surveys conducted regularly by the Ministry of Health and Child Welfare in the region 
showed little or no infection with other helminths and a low S. mansoni prevalence 
(<5%). The selected villages had not been included in the National Schistosome 
Control Programme and therefore had not received treatment for schistosomiasis or 
other helminth infections. The main activity in these villages is subsistence farming. 
Drinking water is collected from open wells while bathing and washing is conducted in 
two main rivers in the villages. Most families maintain a garden located near the river 
where water is collected for watering the crops and the schools surveyed were all in 
close proximity to rivers. 
Study subjects  
The study participants are described in detail elsewhere (27). Briefly, only permanent 
inhabitants of the villages who had never been treated for any helminth infection were 
eligible for inclusion in the study. Informed consent was obtained from all participants 
prior to enrolment into the study. Following explanation of the project aims and 
procedures to the community, school children and their teachers, an initial parasitology 
(stool and urine samples) and serology (blood sample) survey was conducted amongst 
all compliant participants. A questionnaire survey confirmed that on average, all 
participants frequented water contact sites at least four times per week and that 
frequency of water contacts at the various sites was not significantly different within the 
age range included in this study (data not shown). 
 
Parasitology samples (at least 2 urine and 2 stool samples collected on 3 three 
consecutive days) and 20mls of venous blood were collected from each participant. 
Stool samples were processed following the Kato-Katz procedure (28) to detect S. 
mansoni eggs and other intestinal helminths, while the urine filtration method (29) was 
used to detect S. haematobium eggs in urine samples. After collection of the samples, 
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all participants were offered treatment with the recommended dose of praziquantel, 
40mg/kg body weight. In order to be included in the cohort, participants had to meet all 
the following criteria: 1) have provided at least 2 urine and 2 stool samples on 
consecutive days for detection of helminth parasites; 2) have given a blood sample for 
serological assays; 3) be negative for intestinal helminths and S. mansoni. In practice, 
all people meeting criteria 1 and 2 were egg negative for intestinal helminths and S. 
mansoni and so no participants were excluded on this third criterion. 215 people (110 
male and 105 female) aged from 5 to 18 years met all criteria. Serum samples 
obtained from 20mls of venous blood from each participant were frozen and stored in 
duplicate at –20oC in the field and transferred to a –80 oC freezer in the laboratory. One 
complete set of the samples was subsequently transported frozen from Zimbabwe to 
the UK, stored at -80 oC and defrosted for the first time for use in this study. A  serum 
pool for use as a positive control in the western blot assays was made using equal 
volumes (50ul) of sera  from each of the 215 participants irrespective of their 
schistosome infection status and frozen in aliquots which were defrosted only once for 
the immunoassays.  
 
Parasite antigens 
Adult worm antigens were used in this study as previous studies have shown that 
adult S. haematobium parasites suffer immune attrition and are targeted by host 
antibodies (30). Soluble S. haematobium adult worm antigens (SWAP) were obtained 
freeze dried, from the Theodor Bilharz Institute in Egypt and reconstituted as 
previously described (27). These were used in the subsequent gel-electrophoresis 
and immuno-assays. 
 
Antibody enzyme linked immunosorbent assays  
Circulating levels of IgA, IgE, IgG1, and IgG4 directed against the S. haematobium 
adult worm antigens were detected by indirect enzyme linked immunosorbent assays 
(ELISA) as previously described [5] using 5ug/ml of antigen to coat plates, sera 
diluted at 1:50 and the secondary horseradish peroxidase conjugated secondary 
antibodies IgE (Sigma A9667), IgG1(The Binding Site, AP006)  and IgG4 (Ap009), all 
at 1:1000 dilution, and IgA (Dako,P0216) which was diluted at 1:2000. Negative 
control sera from 5 European volunteers’ who have never travelled to tropical 
countries and therefore presumed not previously exposed to schistosomiasis were 
also included in the assays to generate reactivity cut-off points  
 
Gel electrophoresis  
Page 6 
The soluble adult worm antigen preparation was separated into constituent proteins 
by two dimensional gel electrophoresis on 13cm gels  as previously described (27) to 
generate a reference gel used for identifying proteins (200 µg of SWAP used) and 
the second (100 µg of SWAP used) for western blotting  to determine which antigens 
were recognised by the sera following a previously established protocol [5]  
 
Determining sera and secondary antibody dilutions for western blotting 
To minimise differences in sensitivity and specificity of the different assays arising 
from technical differences, assays were optimised by titration assays. A pool of sera 
from all the Zimbabwean participants was used as a positive control while a pool of 
sera from 5 European volunteers (same as the ones used in the ELISA assays 
above) was used as a negative control. The dilutions used for the sera and 
secondary antibodies (IgA, IgE, IgG1 and IgG4) were determined by a combination of 
Enzyme Linked Immunosorbent Assay (ELISA) titration assays and trial western 
blots. First, ELISAs were conducted (varying both secondary antibody (1:500-1:2000) 
and sera dilutions (1:10-1:11280; see example in Supplementary Figure 1) with 
5ug/ml of adult worm antigen. This informed the subsequent trial western blots 
conducted using sera diluted at 1: 200 or 1:400 to allow enough sample for all 
replicate assays and to test a range of potential secondary antibody dilutions 
(1:1000, 1:2000, 1: 4000) on a blot of 100 ug of 2d-electrophoresis-seperated SWAP. 
From these data, we determined dilutions that gave the most consistent replicates 
and optimal sensitivity and specificity for each antibody isotype. Higher dilutions of 
secondary antibodies resulted in the detection of fewer antigenic spots (see 
supplementary Figure 2) while reducing the secondary antibody dilution factor from 
1:1000 (IgE, IgG1, IgG4) or 1:2000 (IgA) resulted in higher background rather than 
an increase in the number of spots detected. Furthermore, sera and secondary 
antibody dilutions used were consistent with those we have previously used in ELISA 
(25, 31) and western blot assays [17] enabling our results to be related to previous 
studies. The finalised protocol is described below. 
 
Western Blotting 
Western blotting was used to determine the proteins reactive with the isotypes IgE, 
IgG4, IgA and IgG1 in sera from the participants. To achieve this, proteins were 
transferred from the gel onto nitrocellulose membrane as previously described (27). 
Blots were run in pairs (one gel/membrane) in order to probe for two antibody 
isotypes at a time in parallel assays. To verify efficient transfer of SWAP proteins, 
membranes were stained with Ponceau S solution (Sigma) to and then blocked for 1 
Page 7 
hr at room temperature in TBS blocking buffer (Pierce) with 0.05% Tween 20. This 
was followed by 2 x 10 min washes with TBS / 0.05% Tween 20 / 0.5% Triton-X 100 
(TBS/TT) (used for all washes). The pool of positive control sera (diluted at 1:200 in 
TBS blocking buffer with 0.02% Tween 20) was added to each of the membranes 
and incubated overnight at 4oC followed by 3 x 10 min washes. Horseradish 
peroxidise-conjugated secondary antibodies diluted in TBS blocking buffer / 0.05% 
Tween 20 were then added to respective membranes diluted at 1:1000 for IgE and 1: 
2000 for IgA. Membranes were subsequently incubated at room temperature for 1 hr, 
followed by 4 x 10 min washes in TBS/TT and 1 x 10min wash in TBS alone. The 
proteins were visualized using the chemiluminescence product ECL Plus (GE 
Healthcare) according to the manufacturer’s instructions. Films exposed to the blots 
for 5 sec were developed and spots matched to the Coomassie blue stained 
reference gel using the image analysis software Image master. Following 
visualisation, the membranes were stripped of the ECL reagent, secondary antibody 
and sera following the manufacturer’s protocol. The same membranes were then re-
probed using the same pool of sera, The IgE membrane was re-probed with IgG4 
diluted at 1:1000 while the IgA membrane was re-probed with IgG1 diluted at 1:1000. 
A previous assay showed that the stripping procedure removed all proteins not 
directly bound to the nitrocellulose membrane as indicated by the lack of ECL 
reactivity with a stripped membrane. This procedure did not remove any of the 
parasite proteins as evidenced by probing the same membrane with three serum 
samples successively, i.e. sera from the endemic population, followed by negative 
control sera (a pool from 5 Europeans who had never travelled to tropical regions) 
then the same sera from the endemic population. An example of a membrane blotted 
with negative control sera and the IgG4-specific secondary antibody is shown in 
Supplementary Figure 3.. Gel electrophoresis and western blotting was repeated 
twice using the secondary antibodies in different order on the same membrane i.e. 
IgG1 followed by IgA and IgG4 followed by IgE to confirm the recognition patterns 
obtained. 
  
Image Analysis and Mass Spectrometry 
Images from the western blots were electronically scanned for image analysis. Spots 
on these blots were detected by pixel analysis and matched across the different blots 
for each isotype using the 2-d gel image analysis software ImageMaster from GE 
Healthcare.. All electronic spot identifications and predicted matches were manually 
verified via independent visualisation by   two researchers. Spots on the Coomassie 
blue stained gel, which matched to those on the western blots, were excised, 
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digested with trypsin and analysed by mass spectrometry analysis as previously 
described (27). Data thus obtained were- submitted to an MSMS ion search via the 
Mascot search engine (Matrix Science), searching both locally established databases 
for S. mansoni EST sequence and the current non-redundant NCBI database. 
 
Data analysis 
The ratios of IgG1/IgA and IgE/IgG4 were calculated for each individual from 
ELISA data for each individual. Partial correlations were conducted to 
determine the association between the ratios and schistosome infection 
intensity allowing for residential village, age and sex. Significance level for the 
statistics tests was set at p <0.05.  For all analyses of antigenic spots, if the 
recognition intensity of the spot after subtraction of the background intensity was 0 
pixels then the spot was designated ‘not recognised’  by the isotype, if it was greater 
than 0, then the antigenic spot was designated as ‘recognised’. To allow 
comparisons of the intensity of antigen recognition by the different isotypes, the 
detected spots were categorised by their recognition intensity into 5 groups; Group 1 
comprised all antigens not recognised by the pooled sera and groups 2-5 were based 
on the interquartile ranges for each isotype using the mean intensity from the 3 
replicate blots per isotype. The interquartile ranges were calculated from the antigens 
using a spot detected from pixel analysis and manual verification. These ranges were 
calculated for each isotype separately so that the spot intensities were standardised 
within the gel. The intensity categories rather than absolute values could then be 
compared across the different gels. This approach was used as it does not require 
any spots to be recognised equally by the 4 isotypes for calibrating recognition 
intensity across all isotypes.  
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Results 
Levels of IgA, IgE, IgG1 and IgG4 detected in individuals.   
The S. haematobium infection prevalence in the participants was 57% and the 
corresponding mean infection intensity was 36 eggs/ 10ml urine (SE of the mean = 
5.7), with individual egg counts ranging from 0 to 676 eggs/10ml urine.  Individual 
infection intensity followed the typical age-infection profile for schistosome infections, 
rising with age to peak in childhood and then declining thereafter as shown in Figure 
1A. The levels of the four antibody isotypes IgA, IgE, IgG1 and IgG4 directed against 
adult worm antigen were  measured for each individual who was included in the 
serum pool. A participant was considered reactive for an isotype if their titre was 
above the cut-off point of mean +2 standard deviations of the negative control sera. 
Based on this cut-off point, the least prevalent schistosome-specific isotype was IgA 
being detected in 31 % of the participants, then IgE detected in 50 % of the 
participants. IgG1 was detected in 58% of the participants while IgG4 was the most 
prevalent response, detected in 74% of the participants. Levels of the isotypes  
were plotted by age groups in Figure 1B.  
 
Earlier studies have shown that higher ratios of IgG1/IgA and IgE/IgG4 are 
associated with lower infection levels (11, 32). Therefore to determine whether the 
relationship between S. haematobium infection and antibody responses in this study 
was consistent with those reported from other earlier studies the ratios of IgG1/IgA 
and IgE/IgG4 were calculated and plotted against schistosome infection intensities. 
The ratio of IgE/IgG4 showed a significant inverse relationship with schistosome 
infection intensity (r= -0.21, p =0.002, df = 210), so that people with high values for 
these ratios carried little or no schistosome infection (Figure 1C). The IgA/IgG1 ratio 
did not show a significant association with infection intensity (r= 0.11, p =0.10, df = 
210). The subsequent Western blotting analyses were performed to determine if 
these different isotypes recognised the same individual native antigens.   
 
Antigens recognised by the different isotypes 
The potential repertoire of schistosome antigens recognised on 2-dimensional blots 
of adult parasite extract was first defined with a highly reactive positive post-
treatment serum pool made from a subgroup of this population previously used to 
investigate the effects of praziquantel treatment on schistosome-specific responses 
(27), which was probed with a secondary antibody combination reactive to 
IgA/IgG/IgM. This serum pool reacted with a total of 71 spots compared to negative 
non-endemic sera which reacted with none of the protein spots. The 71 proteins were 
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identified  and characterised in our previous study (27) which gives their predicted 
molecular weights, isoelectric point (pI), Mascot output statistic, and accession 
numbers from NCBI.  
 
Compared to the IgA/IgG/IgM positive control, no single isotype in the serum pool 
recognised all the 71 antigenic spots. The differences in recognition of the antigenic 
spots between the isotypes were both qualitative and quantitative.  IgG1 recognised 
the largest number of spots (n=45) followed by IgA and IgE which both recognised 39 
spots, with IgG4 recognising the fewest antigenic spots (n=35) as shown in Figure 2 
and Table 1. The most strongly recognised antigens by all the subclasses were the 
two isoforms of glyceraldehyde-3-phosphate, some isoforms of heat shock protein 
(HSP) 70  as well as some proteins still to be identified (spots 60 and 61). The 
antigenic spots 2 (protein yet to be indentified), 6 (triose-phosphate isomerase) and 
15 (yet to be identified) were strongly recognised by IgG1 but were not detected by 
any of the other isotypes. There were 2 isoforms of fructose-1-6-bis-phosphate 
aldolase, one reactive with IgA (antigenic spot 25 in Figure 2A) and one reactive with 
IgG1 (antigenic spot 23 in Figure 2A). Some antigens were not recognised at all by 
any of the 4 isotypes tested; these included the muscle proteins myosin (heavy and 
light chain), tropomyosin and paramyosin, HSP 60 and some isoforms of enolase, 
and immunophilin. Some antigenic spots such as those between spots 22 and 52 in 
Figure 2 were strongly recognised by the sera but were in such low abundance in the 
Coomassie reference gel that they could not be isolated and identified by mass 
spectrometry as reported in previous studies (27, 33). 
 
To quantify the relationships between protein spot recognition by different isotypes, 
the intensity of recognition of each antigenic spot by each isotype was categorised by 
interquartile range (to reduce the effects of differences arising due to intra-isotype 
variation in detection thresholds) as shown in Table 1. The recognition intensity of the 
spots was positively correlated so that for most spots, those intensely recognised by 
IgA were also intensity recognised by IgG1 (Figure 3A). 36 of the 39 antigenic spots 
recognised by IgA were also recognised by IgG1 (Table1). However, IgG1 
recognised an additional nine spots indicated in Figure 3A (numbered spots on the y 
axis). These resolved to the antigens fatty acid binding protein (Sm14), 
phosphoglycerate kinase, triose-phosphate isomerase, an isoform of fructose 1-6-
bis-phosphate aldolase, HSP 70, calreticulin, and two proteins yet to be identified 
(spots 2 and 15) . Conversely IgA recognised three antigenic spots not recognised by 
IgG1 (numbered spots on the x-axis of Figure 3A). These were an isoform of enolase 
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an isoform of fructose 1-6-bis-phosphate aldolase and a protein (spot 50) yet to be 
identified. These were also not recognised by IgG4 (Figure 3D) or IgE (Figure 3F).  
 
Similar patterns of correlations between isotypes, but with some antigens being 
exclusively or largely recognised by only one isotype, were seen in all other pairwise 
comparisons (Fig 3). IgE recognised all 34 antigenic spots recognised by IgG4 as 
shown in Table 1 and Figure 3B. In addition it also recognised an isoform of 28kDa 
glutathione-S-transferase, phosphoglycerate kinase, actin 1, calreticulin and one 
protein (spot 16) still to be identified.  
 
Of all the recognised antigens, only triose-phosphate isomerase (spot 6 in Figure 2 
and Table 1), isoforms of fructose 1-6-bis-phosphate aldolase (spots 23 and 25), 
enolase (spot 26), HSP70 (spot 29) and spots 2 and 15 which are proteins still to be 
identified were recognised by a single isotype. The isoforms of fructose-1-6-bis-
phosphate aldolase, were reactive with either IgA (antigenic spot 25 in Figure 2A) or 
IgG1 (antigenic spot 23 in Figure 2A) but not both.  IgG1 recognised all the antigenic 
spots recognised by IgG4 (Table 1, Figure 3C) and IgE (Table 1, Figure 3E).  
 
Of the current World Health Organisation’s 10 schistosome vaccine candidates, only 
three were recognised by all the isotypes assayed. These were an isoform of 28kDa 
glutathione-S-transferase (spot 8), both isoforms of glyceladeyde-3 –phosphate 
(spots 21 and 22) and several isoforms of actin-binding/filamin-like protein (spots 66-
69). The vaccine candidate paramyosin was not recognised by any of the antibodies 
assayed.  
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Discussion 
Passive transfer studies in animal models show that antibodies can protect against 
schistosomiasis (6-9, 34). In parallel, human immuno-epidemiology studies have 
shown that some antibody classes are associated with low levels of infection in 
endemic populations as well as low re-infection rates following treatment with anti-
helminthic drugs (11, 13, 14, 35-37). However, all previous studies to date have 
focused on describing antibody responses either to individual recombinant antigens or 
to uncharacterised ‘whole worm’ antigen preparations. We have previously defined 
native schistosome adult proteins recognised by the total IgG fraction of human serum 
from samples collected from this same population (27). In this study, we compare the 
reactivity of different isotypes to the soluble component of adult worm crude antigen, 
separated into its constituent defined antigens, to answer two questions. Firstly, which 
antigens are recognised by the different antibody iostypes IgA, IgE, IgG1 and IgG4? 
Second, do different isotypes recognise the same antigens? It is possible that 
observed differences in recognition intensity reflect not only the biological (functional) 
differences between the isotypes but also differences in the sensitivity and specificity of 
the isotypes, so that some antigens would be below the detection limit of the assays. 
However, we have carefully calibrated dilutions of sera and secondary antibodies to 
enable optimal comparison and minimise this possibility.  We have used 3 replicates of 
each blot to verify the patterns and ratios of recognition intensity of each protein spot 
that we observed for each of the 4 isotypes. Thus we have shown that some antigens 
from within the adult S. haematobium proteome are preferentially recognised by certain 
isotypes. For example, one isoform of the antigen fructose-1-bis-phosphate aldolase 
was intensely recognised by IgA but not detected by IgE, IgG1 or IgG4. Furthermore 
comparing recognition intensity between isotypes using quartiles calculated within each 
subclass (Table 1), rather than absolute values (Figure 3), corrected for some intra-
isotype variation in sensitivity. The study was designed to extend our understanding of 
the individual antigens detected in immunoassays routinely conducted by ELISA using 
crude antigens. In these former assays, protocols are designed to optimise sensitivity 
and specificity as done here to reduce the effects of differences in detection thresholds 
of the different isotypes.  
 
The 4 isotypes we investigated detected a total of 48 antigenic spots out of a possible 
71 spots detected with total IgG antibodies previously described by screening adult 
worm antigens with post-treatment sera (27). The sera used in this current study were 
from 7-18 year olds before enhancement of antibody reactivity with anti-helminthic 
treatment (27). Our previous study involved older people i.e. up to 42 years old and 
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included the reactivities of the additional IgG subclasses IgG2, IgG3 which are reactive 
against some of the schistosome vaccine candidates (24). Therefore, it is not 
surprising that the number of spots recognised by the IgG subclasses (IgG1 and IgG4) 
in this study would be fewer than in previous studies. Comparing the number of 
antigenic spots detected and the prevalence of the response in the study population, it 
is interesting that while IgG4 was the most prevalent response in the study population 
(present in 74% of the population), this isotype detected the least number of antigenic 
spots suggesting that there are few dominant antigens stimulating the IgG4 response. 
Conversely, IgG1 detected in 58% of the participants, recognised the largest number of 
spots suggesting that the IgG1 response is directed against a larger repertoire of 
antigens than the other isotypes.    
 
We have previously shown a dichotomous association between IgA and IgG1 
responses directed against adult worm antigens in a different Zimbabwean population 
(14) and the spot identification in Figure 3A shows that there are some antigens 
recognised either by IgG1 or IgA but not by both antibodies. An inverse relationship 
has also been reported in a case of idiopathic arthritis where patients deficient in IgG1   
had high titres of IgA (38) suggesting that the expression of these two subclasses is 
differentially regulated. IgG1 recognised the largest number of antigenic spots: 45 
including 8 of the 10 of the WHO’s schistosome vaccine candidates. Furthermore, in 
this study, IgG1 levels rose with age to peak in the oldest age group with the least 
infection suggesting that the antibody is associated with protection against infection. 
This is consistent with our previous studies showing an association between anti-worm 
IgG1 responses and protection to S. haematobium infection (14). IgA recognised fewer 
antigenic spots than IgG1, reacting with only 3 of the 10 schistosome vaccine 
candidates including the leading vaccine candidate 28kDa glutathione-S-transferase.  
 
The ratio of IgE to IgG4 levels has previously been associated with protection to re-
infection by S. haematobium infection (11) and the association of a high IgE/IgG4 ratio 
with little or no infection in our present study is consistent with these findings. The 
inverse relationship between IgG4 and IgE has been used to suggest that IgG4 
antibodies might block IgE effector functions by competitively binding to epitopes 
recognised by both isotypes and thereby inhibit IgE-dependent cell cytotoxicity 
mediated by monocytes, eosinophils or platelets (12, 39). The IgG4 subclass is up-
regulated in association with anti-inflammatory factors(for example, IL-10 (40)) and its 
own anti-inflammatory characteristics are thought to help the immune system to 
dampen inappropriate inflammatory reactions (41). This would only be possible if the 
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two isotypes recognised the same antigens. In this study, IgG4 bound to the fewest 
antigenic spots while IgE recognised all those recognised by IgG4. IgE reacted with 7 
of the 10 vaccine candidates, 5 of which were also recognised by IgG4.  The 
recognition intensities (for each antigenic spot. representing both affinity and avidity) of 
these two antibodies were the most strongly correlated in the study suggesting a tightly 
regulated association between them. Earlier studies in filariasis using western blotting 
of one dimensional gels  indicated that the level of cross reactivity between IgE and 
IgG4 differed with the level of pathology (42) which suggests that during the course of 
infection,  there is dissociation in antigen recognition patterns between the two 
antibodies. How this dissociation occurs is unclear but may be related to the order of 
antibody class switching where IgG4 secreting B cells can switch to IgE but not the 
converse (43) and/or a threshold being reached in antigen levels (33).  
 
The antigens recognised by IgE but not IgG4, and by IgG1 but not IgA, are of interest 
since they may be associated with the development of resistance to schistosomiasis; 
this is supported by the fact that most of these antigens are already known vaccine 
candidates (24). Studies are now underway to identify the proteins which were not 
serologically reactive, particularly those that are abundant in the soluble proteome 
which might play an important role in  immune evasion and/or modulation of the host 
immune response (44). Similarly there is a need to identify the intensely recognised 
proteins which occurred at insufficient concentrations in the adult worm proteome to be 
identified by mass spectrometry, as these may indicate highly immunogenic vaccine 
candidates as yet undiscovered.  
 
Overall, our study has indicated that although the majority of the antigens are 
recognised by all the four antibody isotypes tested, there may be restriction in 
antigen recognition for some antigens, for example prevalent isotypes such as IgG4 
appear to react to relatively few of the major adult worm antigens. This may partly 
explain differences observed in population level isotype dynamics in human 
schistosomiasis. Furthermore, there are differences in the recognition of isoforms of 
some antigens such as the leading vaccine candidate, 28kDa glutathione-S-
transferase and glyceraldehyde-3-phosphate dehydrogenase. These isoform-specific 
differences are an important consideration for vaccine development, where 
recombinant vaccines lack post-translational modifications and therefore epitopes 
crucial for induction of the relevant isotype-specific antibody responses. Studies on 
antigen recognition patterns by different antibodies present in sera from 
individuals or partitioning the study population by age and infection status as 
Page 15 
we previously reported for total IgG will be valuable for identifying further 
vaccine candidates (33).  
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Figure legends 
 
Figure 1: Description of the individual study participants partitioned by age group. (A) 
Infection intensity for each individual calculated as a mean of eggs /10ml of urine 
from at least 2 urine samples collected on consecutive days. (B) Antibody levels 
measured as optical densities for each individual (C) The relationship between the 
ratios of IgG1/IgA and IgE/IgG4 calculated from the values in (1B) above and 
schistosome infection intensity for each individual participant. These show a 
significant negative association between the ratio IgE/IgG4 and infection intensity 
and no significant association between the IgG1/IgA ratio and infection intensity.  
Figure 2: Antigen recognition patterns of the serum pool compared by 2-
dimmensional western blotting. (A) IgA vs. IgG1. (B) IgE vs. IgG4 
 
Figure 3: Comparison of recognition intensity for each antigenic spot by the different 
isotypes showing a significant positive correlation between all 4 isotypes. Italicised 
numbers refer to the spot identity of antigenic spots preferentially recognised by one 
of the two isotypes and their protein identities are given in Table 1.  (A) IgG1 vs. IgA. 
(B) IgG4 vs. IgE. (C) IgG4 vs. IgG1. (D) IgG4 vs. IgA.  (E) IgE vs. IgG1.  (F) IgE vs. 
IgA.  
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Tables  
 
Table 1: The table gives identities of the antigenic spots in Figure 3, relating the spot 
number to its protein identity from the peptide searches and recognition intensity by 
each of the isotypes. The WHO-listed schistosome vaccine candidates are 
highlighted in bold. The intensity of recognition is coded from no colour       (antigenic 
spot not detected), very light       , 1st quartile, (excluding the undetected spots in 
former category, i.e. recognition intensity >0 ), light        (2nd quartile), medium        
(3rd quartile) and darkest           (4th quartile). The inter-quartile ranges were 
calculated separately for each isotype.  
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 Spot Protein name IgA IgG1 IgE IgG4 
1 Fatty acid-binding protein Sm14         
2 No significant hit         
3 Myosin light chain          
4 Putative mucin-like protein          
5 Putative mucin-like protein          
6 Triosephosphate isomerase          
7 28kDa glutathione-S transferase       . 
8 28kDa glutathione-S transferase         
9 Phosphoglycerate kinase         
10 Myosin heavy chain          
11 Proteasome subunit         
12 14-3-3 epsilon          
13 Myosin heavy chain          
14 Heat shock protein HSP70          
15 No significant hit     .   
16 ENSANGP00000014266         
17 Phosphoglycerate kinase .       
18 Putative mucin-like protein          
19 Tropomyosin 1          
20 Tropomyosin 2          
21 Glyceraldehyde-3-phosphate dehydrogenase          
22 Glyceraldehyde-3-phosphate dehydrogenase          
23 Fructose 1,6 bisphosphate aldolase         
24 Actin         
25 Fructose 1,6 bisphosphate aldolase          
26 Enolase          
27 Enolase         
28 Fimbrin          
29 Heat shock protein HSP70        
30 Actin 1        
31 Actin          
32 Actin         
33 Actin         
34 Actin          
35 Immunophilin         
36 Immunophilin         
37 No significant hit         
38 Calreticulin           
39 Protein disulfide isomerase         
40 Enolase         
41 Enolase          
42 Enolase          
43 Enolase          
44 Putative mucin-like protein          
45 Enolase          
46 Enolase          
47 Enolase          
48 Putative cytosol aminopeptidase         
49 Putative cytosol aminopeptidase         
50 No significant hit         
51 No significant hit         
52 No significant hit         
53 ENSANGP00000019187          
54 Phosphoglucomutase          
55 No significant hit         
56 Phosphoglucomutase          
57 Heat shock protein HSP60          
58 Predicted Zn-dependent peptidases         
59 No significant hit         
60 No significant hit         
61 No significant hit         
62 No significant hit         
63 Heat shock protein HSP70          
64 Heat shock protein HSP70          
65 Heat shock protein HSP70          
66 Actin-binding/filamin-like protein          
67 Actin-binding/filamin-like protein          
68 Actin-binding/filamin-like protein          
69 Actin-binding/filamin-like protein          
70 Paramyosin         
71 No significant hit         
Table 1 
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